Press Releases

CluePoints Launches Medical & Safety Review (MSR) Software to Revolutionize Clinical Data Review

CluePoints furthers its commitment to delivering innovative solutions that enhance clinical trial efficiency with this latest addition to its enterprise software platform

CRDSA Announces Publication of Standards for Clinical Trial Data Reuse

The Clinical Research Data Sharing Alliance (CRDSA), a multi-stakeholder consortium that serves the clinical research data ecosystem, has announced the publication of two new standards; the Standard for Sharing Clinical Study Data and the Standard for Secondary Analysis of Clinical Study Data. CRDSA developed these standards in response to common challenges faced by both data contributors and researchers. These new standards aim to facilitate the responsible sharing and use of anonymized individual patient data from clinical studies to support the research community and accelerate the discovery and delivery of new therapies to patients.

Duke Street Bio Granted Approval by European Medicines Agency to Launch Next-Generation PARP1-Selective Inhibitor Trial

Duke Street Bio Ltd has announced that the European Medicines Agency (EMA) has granted approval to commence a clinical trial for its highly-selective PARP1 inhibitor, DSB2455.

Phastar Announced as 2024 Scrip Award Finalist for Best Contract Research Organization – Specialist Provider

Phastar’s Data Analytics and Visualization Portal and commitment to high ESG standards secures shortlist spot at the 20th Anniversary Scrip Awards

Headlands Research to Open New Clinical Research Site in El Paso, Texas, Further Commitment to Improving Diversity in Clinical Research

Headlands Research, a leading multinational network of clinical trial sites, today announced it will launch a new clinical research site in El Paso, Texas in Q4, expanding clinical trial access to a large, traditionally underserved Hispanic population. The site will focus on metabolic/endocrine, healthy volunteer/vaccine, and pain clinical trials.

eClinical Solutions Announces Growth Investment by GI Partners to Further Its Mission of Helping Bring Treatments to Patients Faster

eClinical Solutions LLC, a global provider of digital clinical software and services, today announced that GI Partners, a private investment firm, has made a majority investment in the company to advance the future of digital trials via continued enhancements to its leading AI-powered data products and biometrics services.

Quotient Sciences and Vasa Therapeutics Announce Dosing of First Subjects with VS-041, a Novel Heart Failure Treatment

PharmaForceIQ Announces Majority Investment by Eir Partners to Support and Accelerate Growth

PharmaForceIQ Announces Majority Investment by Eir Partners to Support and Accelerate Growth Miami, FL – 10th September 2024, PharmaForceIQ (PFIQ), the leading end to end Omnichannel Solution for Pharmaceutical Marketing, Medical and Clinical teams today announced a significant investment by Eir Partners (Eir) to accelerate adoption of the company’s unique technology platform and services for the Life Science industry.

Symbiosis announces acquisition of new facility and investment in automated commercial scale GMP sterile manufacturing capability supported by £4.3m grant from Scottish Enterprise

Global CDMO brings technological advancements & significant capacity to Ocean County, NJ location

Indica Labs and Paige Forge Strategic Partnership to Expand Integrated AI for Anatomic Pathology Labs

Indica Labs and Paige have formed a non-exclusive partnership aimed at integrating Paige’s Diagnostic AI models into Indica’s robust Anatomic Pathology workflow management software, HALO AP®.

International Consortium to Revolutionize Viral Vector Manufacturing

Abselion has announced the collaboration of leading biotechnology companies and research organizations in UK and Canada to develop next-generation cell platform for viral vector production.

Biopharma PEG Expands Multi-Arm PEG Product Line for Medical and Biopharma Applications

Phastar named in 2024 Environment 100 List

Phastar named in 2024 Environment 100 List Phastar continues to lead the CRO industry in corporate responsibility as CEO Graham Clark is named in list of trailblazers, innovators and visionaries.

eClinical Solutions Introduces Protocol Deviations Among New Product Innovations Boosting Operational Success for Clinical Trials

eClinical Solutions announced newly released product enhancements and AI-enabled functionality within the elluminate Clinical Data Cloud ®. Recent platform updates offer clinical teams increased oversight and efficiency amid trial complexity and advance the AI technology footprint of life sciences organizations.

PathAI Announces Launch of AI-based Measurement of Metabolic Dysfunction-Associated Steatohepatitis ("AIM-MASH") on the AISight Image Management System

PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, is proud to announce the launch of its AIM-MASH product on the AISightⓇ1 Image Management System (IMS). This product provides advanced AI-based measurement (AIM) to support the analysis of MASH Clinical Research Network (CRN) Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Activity Score (MAS) component grades and fibrosis staging. The launch of AIM-MASH on AISight aims to increase the reproducibility and scalability of pathologists' assessments and management of MASH cases, which are projected to reach 27 million in the US alone by 2030.

Abzena Supplies Clinical Trial Material for Angiex’s Phase I Study of AGX101, a First-in-Class TM4SF1-directed ADC

Brijesh Patel Named New CEO at ECI

ECI (Enhanced Compliance Inc.), a leading provider of regulatory, quality and engineering services and solutions for the life sciences industries, today announced the appointment of Brijesh Patel as the company’s new Chief Executive Officer (CEO), replacing Hoyt Randall Smith, who has announced his retirement.

TEDDY Selects Infinity Bio to Provide Antibody Reactome Services for Large Study

Infinity Bio has been chosen by The Environmental Determinants of Diabetes in the Young (TEDDY) study to provide antibody reactome services. This collaboration aims to advance the understanding of environmental factors contributing to type 1 diabetes. Infinity Bio’s innovative technology will be used to analyze antibody responses, offering critical insights for diabetes research. This partnership signifies a major step forward in biomedical research, with the potential to enhance diabetes prevention and treatment strategies.

Rho names renowned neurologist Andrew Feigin, MD, as Chief Medical Officer

Rho, a full-service contract research organization (CRO), has appointed leading neurologist Dr. Andrew Feigin as its new chief medical officer (CMO). In this pivotal global role, Dr. Feigin will provide strategic medical and operational expertise across multiple therapeutic areas, ensuring the integrity and safety of Rho’s clinical trials. Dr. Feigin's career is marked by groundbreaking contributions to neurology and clinical research. He served as the site principal investigator on more than 30 clinical trials, notably spearheading the first phase 1 clinical trial using gene therapy for Parkinson's disease. His prolific contributions to the field include over 150 peer-reviewed articles and numerous advisory board positions.